External Committees

ICER has an advisory board which provides strategic guidance to ICER’s leadership team. Each of ICER’s core programs also has a non-governing advisory board. Composed of leading representatives from provider groups, public and private payers, patient groups, and purchasers, the program advisory boards help ensure that all reviews are actionable for a variety of stakeholders.

Advisory Board

  • Harold Carter, PharmD, Senior Director, Clinical Solutions, Express Scripts
  • Wendy Everett, ScD, Vice President, Advisory Services, Avalere Health
  • Patrick Gleason, PharmD, Assistant Vice President, Health Outcomes, Prime Therapeutics
  • Beth Hamilton, MBA, Vice President, Global Oncology Market Access & Pricing (OMAP), AstraZeneca
  • Ross Hoffman, MD, Chief Medical Officer, Envolve Pharmacy Solutions
  • Kjel A. Johnson, PharmD, Vice President, Specialty Strategy and Client Solutions, CVS Health
  • Myoung Kim, PhD, MBA, Vice President and Head, US Heath Economics and Outcomes Research and Medical Access, Novartis
  • Andreas Kuznik, PhD, Senior Director, Health Economics and Outcomes Research, Regeneron Pharmaceuticals
  • Chris Leibman, PharmD, Senior Vice President, Value and Access, Biogen
  • Bryan Loy, MD, Market Medical Officer, Humana
  • Mark McClellan, MD, PhD, Founding Director, Duke-Margolis Center for Health Policy, Duke University
  • Sharon Phares, PhD, Chief Scientific Officer, National Pharmaceutical Council
  • Brian Meissner, PharmD, External Strategies and Value Based Experimentation Team Lead, AbbVie
  • Ron Preblick, PharmD, Senior Director, Global Business Partner, General Medicines in Health Economics & Value Assessment (HEVA) / Global Market Access, Sanofi
  • Sulabha Ramachandran, PhD, Vice President, US and Regions, Value Evidence and Outcomes, GlaxoSmithKline
  • Michael Sherman, MD, MBA, Executive Vice President and Chief Medical Officer, Point32Health
  • David R. Strutton, PhD, Vice President, Global Pharmaceuticals and Policy Evidence Research, Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc.
  • Sean D. Sullivan, PhD, Professor and Dean, University of Washington School of Pharmacy
  • John Watkins, PharmD, Pharmacy Manager, Formulary Development, Premera Blue Cross
  • Jeff White, PharmD, Staff Vice President, Clinical Pharmacy Services, IngenioRx
  • Gergana Zlateva, PhD, Vice President, Patient & Health Impact, Oncology, Pfizer